Xeris Biopharma Hits Day High with 14.16% Surge in Stock Price

Xeris Biopharma Holdings, Inc. has experienced a significant surge in its stock price, gaining 14.16% on October 15, 2025. The stock reached an intraday high of USD 9.29, reflecting strong performance in the pharmaceuticals and biotechnology sector. Over the past month, Xeris has shown a remarkable increase of 25.95%, significantly outperforming the S&P 500, which saw a modest gain of 0.91% during the same period.
In the past year, Xeris Biopharma has delivered an impressive return of 206.95%, compared to the S&P 500's 13.39%. The company's performance over the last three years has also been notable, with a staggering 659.84% increase, consistently surpassing the broader market index.

Despite its recent successes, Xeris Biopharma faces challenges, including a negative book value and a high debt-to-EBITDA ratio. However, the company has reported positive results in its last two quarters, with a significant growth in operating profit. Institutional holdings stand at 65.86%, indicating a strong interest from larger investors who typically have more resources to analyze company fundamentals.